Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04784221
Other study ID # 2020-003671-17
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date September 2027

Study information

Verified date July 2023
Source Centre Francois Baclesse
Contact Delphine LEROUGE, MD
Phone 332455050
Email d.lerouge@baclesse.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously


Description:

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously in recurrent tumors


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date September 2027
Est. primary completion date September 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient aged 18 or over - Patient with tumor of the cephalo-spino-iliosacral axis corresponding to the spectrum of tumors treated in protontherapy, particularly base of the skull, pharyngeal wall, parapharyngeal and retropharyngeal lymph nodes, cavum without associated lymph node, pre-spinal tumor, etc. tumors are immobile as opposed to visceral thoracic, abdominal and pelvic tumors which may be mobile which will be excluded because they cannot be irradiated in proton therapy in the current state of the art), - Tumor already irradiated, within more than 6 months before inclusion - Patient with a relapse or a new tumor in irradiated territory - Tumor considered to be radioresistant (TCD50> 50Gy) - Dosimetry (s) of previous irradiations available - Progressive tumor in tissue already irradiated to at least 40 Gy EQD2 (a / ß = 2) - Indication of reirradiation by protontherapy for curative purposes. The indication for reirradiation by protontherapy will be discussed depending on the size and location of the tumor (particularlyfor a volume of less than or equal to 113 ml of PTV in an ENT situation may be taken into account), the presence of previous toxicities. It will be validated by RCP at the Center François Baclesse - The patient may have received previous systemic treatment - Evaluable disease according to RECIST 1.1 criteria - Performance Status = 2 - Normal renal function: creatinine clearance = 50 ml / min - Patient affiliated to a social security system - Patient having given written consent Exclusion Criteria: - Mobile tumors - Lymphomas, brain tumors (gliomas), meningiomas, skin carcinomas, malignant melanomas (skin or mucous membranes), tumor of the larynx, mobile lesions of the oral cavity - Recurrence occurring within 6 months of the end of the first irradiation - Patient with a contraindication to radiotherapy - Patient with progressive visceral or cerebral metastases - Life-threatening comorbidities within two years - Patient with a contraindication to MRI - Immovable metallic material in the target volume (significant imaging artefacts) - Impossibility of completely immobilizing the target volume (moving organ) - Large volume to be irradiated (PTV) for an acceptable benefit / risk balance evaluated in RCP of the François Baclesse Center - Neoplasic skin ulceration - Doses previously received by OARs or radiation toxicity already present preventing reirradiation including in protontherapy (clinical and dosimetric study of each case) - Concomitant cancer treatment such as chemotherapy, immunotherapy, targeted therapy or other, underway or planned to be initiated during irradiation - Simultaneous participation in another therapeutic clinical trial - Patient deprived of liberty, under guardianship or curatorship - Pregnant or breastfeeding patient - Patient unable to undergo medical monitoring of the trial for geographic, social or psychopathological reasons - History of other malignant disease in the past 3 years, except skin cancer other than melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not show signs of recurrence for at least 3 years

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiation by protontherapy associated to nanoparticles injection
Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles. Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26. The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Centre Francois Baclesse

Outcome

Type Measure Description Time frame Safety issue
Primary Local efficacy of a treatment combining the administration of nanoparticles with proton therapy proportion of patients alive and without local progression two years after the start of proton therapy (local progression-free survival rate) 2 years after the treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT06103617 - Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Phase 2
Completed NCT05364905 - Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Recruiting NCT05396300 - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Not yet recruiting NCT04889742 - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Phase 2
Recruiting NCT05189054 - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Completed NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Not yet recruiting NCT02410187 - SBRT for Extra-cranial Oligorecurrent Tumor Phase 2
Recruiting NCT05855811 - PREventing Second Cancers With DOSTARlimab Phase 2
Recruiting NCT05626829 - Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Phase 2
Completed NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Phase 1
Recruiting NCT06372574 - A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors Phase 1
Completed NCT05200195 - Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling